This podcast is produced by pharmacy faculty to supplement study material and provide relevant drug and professional topics. We're hoping that our real-life clinical pearls and discussions will help you stay up-to-date and improve your pharmacy knowledge.
In this episode, we chat with Eris Tollkuci, PharmD, BCOP regarding what every non-onc healthcare provider should know about immune checkpoint inhibitors (specifically PD-1/PD-L1 inhibitors) in patients with cancer.
In this episode, we discuss the important updates in the 2019 IDSA Community Acquired Pneumonia (CAP) guidelines with Dr. Christie Bertram, PharmD, an Infectious Diseases Clinical Pharmacist and Assistant Professor at Rosalind Franklin University’s College of Pharmacy.
In this episode, we review the three oral P2Y12 inhibitors on the market (clopidogrel, prasugrel, ticagrelor) and discuss each agent’s clinical pearls, comparative effectiveness, and unique precautions.
In this episode, we will discuss what is the latest and greatest from the GINA (Global INitiative for Asthma) 2019 guidelines, including new recommendations regarding rescue inhalers, tiotropium, and azithromycin for asthma.
In this episode, we discuss the newly published DAPA-HF trial, which studied dapagliflozin (a drug for diabetes) among patients who had heart failure with reduced ejection fraction (HFrEF) many of which did NOT have a history of diabetes.
We are proud to announce our 100th HelixTalk episode! In celebration, we sit down with Dr. Marc Abel, the Dean of the College of Pharmacy at RFUMS to discuss the profession of pharmacy and the future of pharmacy education.
In this episode, we enlist the help of Associate Dean for Student Affairs, Janeen Winnike, to discuss the various professional pharmacy organizations and the importance of networking via joining at least one as a student or pharmacist.
In this episode, we review guideline recommendations and recent evidence for secondary prevention of stroke, including risk factor modification, anticoagulant therapy (in patients with atrial fibrillation), and antiplatelet therapy (in patients with noncardioembolic stroke).
In this episode we discuss the recent FDA approval of esketamine (Spravato) for the management of treatment resistant depression as an add on to oral antidepressant therapy. The agent is novel though so, too, may be its adverse effect profile and logistics of administration.
In this episode, we discuss the changes made in the American Diabetes Association’s 2019 Standards of Diabetes Care guideline as well as updates in therapy recommendations per ADA and ESDA consensus statement published in Fall 2018.
In this episode, we take a deep dive into the use of stimulants and other medications for management of ADHD. After decades of use, technology has resulted in changes to how they are administered. Furthermore new agents have become available, but are they an improvement?
In this episode, we discuss IV fluids for hospitalized patients, including normal saline (0.9% NaCl) and lactated ringer’s. In addition, we review the newest literature supporting the use of balanced crystalloids over normal saline from the SMART and SALT-ED trials.
In this episode, we are excited to have a special guest with us. Dr. Dyson Wake is Senior Clinical Specialist in Pharmacogenomics at NorthShore University HealthSystem’s Center for Molecular Medicine here in Chicagoland and is here to explain the current and future applications of pharmacogenomics to the area of personalized medicine, as well as expose some misconceptions.
In this episode, we will discuss a new class of medications for preventing migraines called CGRP antagonists, including an overview of their development, clinical efficacy, and future goals of further research in this area.
In this episode, we discuss a broad overview of insulin topics ranging from the various types of insulins, dosage forms, brand/generic names, pharmacokinetic nuances, injection technique, and a wide variety of clinical pearls.
In this episode, we discuss vaccine related updates with our vaccine expert, Dr. Lauren Angelo. The updates discussed in this episode include the new shingles vaccine, the variety of influenza vaccines on the market, and several other updates.
In this episode, we discuss the importance of accurately recognizing depressive symptoms in patients with kidney disease and provide review the limited available literature regarding treatment in this population. We then discuss guidelines to determine some of the best treatment options for this unique subgroup of patients.
In this episode, we take a closer look at deuteration, specifically involving the medication deutetrabenazine (discussed back in episode 76). We feature a guest contributor from our pharmacy sciences department who assists us as we look at the drug design aspects of this unique molecule and its implications for research moving forward.
In this episode, we interview Kathleen Lynch, PharmD and Ciantel (Adair) Blyler, PharmD, coauthors of the New England Journal of Medicine article, published in March 2018, investigating the role of pharmacist-led interventions for blood pressure reduction in black barbershops.
In this episode, we interview Janeen Winnike, Dean of the Office of Students Affairs at the RFUMS College of Pharmacy, regarding transitions from a student life to a practitioner life. With her previous role as an HR official within a large community pharmacy chain, she offers some “do’s and don’ts” for students transitioning into new practitioners.
In this episode, we discuss five clinical pearls about pulmonary embolism ranging from PE diagnosis, classification, and treatment. We specifically examine when and how alteplase is given for PE and its use with concurrent anticoagulation.
In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.
In the previous episodes, we discussed how we should evaluate a patient’s bleeding and clotting risks as well as looked at recommendation for management for various anticoagulants. In this episode, we will continue the discussion to management of antiplatelets as well as when to resume both antiplatelets and anticoagulants following a procedure.
In this episode, we will discuss some important factors to consider in management of various anticoagulants. We will also provide agent specific pharmacodynamic and pharmacokinetic based recommendations.
In this episode, we discuss the difficulty in identifying adverse drug reactions (ADR) that ACTUALLY occur from a drug therapy, how tertiary drug references (such as Micromedex or LexiComp) may be misleading, and what tips and tricks you can use to recognize the most clinically relevant ADRs for patient counseling.
In this episode, we interview Dylan Moe, PharmD, our very own alumnus, regarding the new Illinois rule requiring patient counseling for all new prescriptions and inquire how the new rule has impacted his pharmacy, work environment, and his opinions on the implementation of the rule.
In this episode, we will discuss the current state of benzodiazepine use, expected trends in prescribing, and risks associated with use. Lastly, we will discuss techniques for ensuring that a benzodiazepine taper is performed in a safe manner with lowest risk of harm.
In this episode, we discuss new evidence for cardiovascular outcomes in diabetics based on the LEADER trial (liraglutide) and CANVAS trials (canagliflozin). We also discuss the new FDA warning for canagliflozin regarding amputation risk.
In this episode, we discuss updates in diabetes management that includes nuances from the ADA’s Standards of Care 2017. We also review some newer pharmacologic agents, a fixed dose GLP-1 agonist and basal insulin combinations.
In this episode, we discuss three "older" antihypertensives that are not preferred first-line therapies: clonidine, methyldopa, and minoxidil. We outline why these agents are not first-line therapies and review their pharmacology and adverse effect profiles.
In this episode, we discuss the history of ergot products for treatment of migraines. We compare their safety and efficacy to newer agents such as the triptans and assess their resultant place in therapy.
In this episode, we discuss several aspects of serotonin syndrome including the typical clinical presentation, its etiology and common drug-induced combinations, and how to appropriately manage the syndrome.
In this episode, we discuss the pathophysiology of embolic stroke in patients with atrial fibrillation and review the use of left atrial occlusion devices, such as the WATCHMAN device, to reduce the risk of stroke in patients with atrial fibrillation without the use of anticoagulants like warfarin.
In this episode, we review the 12 recommendations from the 2016 CDC Guideline for Prescribing Opioids for Chronic Pain. These recommendations are intended to help curb the opioid epidemic and provide guidance to healthcare providers regarding safer use o
In this episode, we discuss the concept of professional advocacy, with a particular focus on how to advocate for the profession of pharmacy and what tools and organizations are available to assist in being an advocate.
In this episode, we discuss with Dr. Megan Hartranft the five oncology drugs that every pharmacist should know about, which is a great review for P4 students who are currently preparing for the NAPLEX. We cover cyclophosphamide, cisplatin, methotrexate, doxorubicin, and vincristine.
In this episode, we discuss the newest definition of sepsis and septic shock according to the Sepsis-3 criteria and the 2016 Surviving Sepsis guidelines. We also review the scoring systems of “qSOFA” and “SOFA” and use a patient case to help demonstrate the new definitions.
In this episode, we discuss the overuse of proton pump inhibitor (PPI) therapy and several concerns regarding chronic use of this medication class, including hypomagnesemia, fracture risk, low seurm B12 levels, anemias, and increased risk of certain infections.
In this episode, we discuss the new FDA categorizations of biosimilars, the legal implications of biologic/biosimilar prescriptions, and the new "follow-on" approval pathway of Basaglar, a new insulin glargine U-100 product.
In this episode, we discuss the SPRINT trial (intensive vs. standard blood pressure control) using a case vignette of Mr. Wilson, a 55 year old patient presenting to a clinic with a blood pressure of 139/89 mmHg.
In this episode, we discuss more of the most important drug interactions, including grapefruit juice with statins and calcium channel blockers, QT prolonging medications, levothyroxine with cations and PPIs, and PDE-5 inhibitors with nitrates.
In this episode, we discuss two new naloxone devices (intramuscular Evzio and intranasal Narcan) and review new state laws that are expanding the role of pharmacists in dispensing these opioid reversal products.
In this episode, we discuss three shocking recommendations from the CHEST 2016 VTE guideline update. We focus on (1) the debate between NOAC, DOAC, or TSOAC nomenclature, (2) the controversial recommendation of preferring NOACs over warfarin in VTE treatment, and (3) the efficacy of compression stocking for prevention and treatment of post-thrombotic syndrome.
In this episode, we discuss RFUMS's Interprofessional Community Clinic (ICC), a student-run clinic providing health services to underserved populations. The students in this episode discuss how the ICC evolved and highlight pearls and challenges in starting and running a free health clinic or screening event.
In this episode, we discuss the self-care of nasal congestion and allergies, including systemic/topical decongestants, nasal corticosteroids, antihistamines, cromolyn, and alternative medicine therapies.
In this episode, we discuss self-care of cough and cold, including using PQRSTA or SCHOLAR-MAC to prompt relevant questions for patients, codeine, dextromethorphan, diphenhydramine, camphor, menthol, and guaifenesin.
In this episode, we discuss the science of carbohydrate-based sugars, sugar alcohols, artificial sweeteners, and natural sweeteners with Dr. Eric Walters, author of the book "The Sweetener Book" and Professor at Rosalind Franklin University.
In this episode, we discuss the BRIDGE trial, which investigated whether patients with atrial fibrillation on warfarin need a parenteral anticoagulant "bridge" in preparation and after an elective surgical procedure.
In this episode, we discuss the many facets of homeopathic medications, including legal status in the United States, safety and efficacy data, and the ethics of homeopathy from the point of view of practicing pharmacists.
In this episode, we have an in-depth review of how to measure glomerular filtration rate (GFR), including variants of the Cockcroft-Gault equation and newer, more accurate methods that may eventually be used to renally adjust certain medications.
In this episode, we review historical and new treatment options for hepatitis C, including: peginterferon, rivabirin, boceprevir, telaprevir, sofosbuvir (Sovaldi), simeprevir (Olysio), ombitasvir/paritaprevir/ritonavir/dasabuvir (Viekira Pak), and ledipasvir/sofosbuvir (Harvoni).
May 18, 2015 - Correction added in the beginning of the episode regarding Viekira Pak dosing regimen.
In this episode, we discuss the pharmacology of oversedation, the importance of sedation minimization strategies in mechanically ventilated patients, and overview the sedatives and analgesics commonly used in this patient population.
In this episode, we discuss the management of overactive bladder, including: oxybutynin (Ditropan, Oxytrol), tolterodine (Detrol), trospium (Sanctura), solifenacin (VESIcare), darifenacin (Enablex), fesoterodine (Toviaz), mirabegron (Myrbetriq), and onabotulinumtoxinA (Botox).
In this episode, we discuss newly approved agents for diabetes mellitus: Afrezza (inhaled human insulin), SGLT2 inhibitors (Invokana, Farxiga, Jardiance), and long-acting GLP-1 agonists (Bydureon, Tanzeum).
In this episode, we review a wide variety of cancer screening guidelines with a particular focus on the two most controversial screening areas: breast cancer screening with mammography and prostate cancer screening with PSA levels.